Cat. No. 2022
Alternative Name: Mifobate
Chemical Name: (4-Chlorophenyl)(dimethoxyphosphiny
Biological ActivitySelective PPARγ antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPARγ transcriptional activity (IC50 = 140 μM) without affecting ligand-stimulated PPARα, PPARβ or FXR transcriptional activity. Inhibits PPARγ-dependent adipocyte differentiation and growth in vitro and in vivo. Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Doggrell (2003) Do peroxisome proliferation receptor-γ antagonists have clinical potential as combined antiobesity and antidiabetic drugs? Expert.Opin.Invest.Drugs 12 713.
Rieusset et al (2002) A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol.Endocrinol. 16 2628. PMID: 12403851.
Nguyen et al (1987) gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity. J.Med.Chem. 30 1426. PMID: 3612689.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SR 202 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SR 202, supplier, Selective, PPARγ, PPARgamma, antagonists, antidiabetic, antiobesity, agent, Peroxisome, Proliferator-activating, Receptors, SR202, Tocris Bioscience, PPARγ Antagonist products
Find multiple products by catalog number
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.